Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vyome Holdings, IncOBLN · Entity 1824 | VP of Operations | October 31, 2017 | November 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vyome Holdings, Inc
Report date October 31, 2017 · Filed November 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,689 |
Reported balance
After 2017-10-31 transaction · row 1
1 source rowRow 1 · 2017-10-31 · Grant · Acquired 942 · Balance 1,689 F1: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2017 Filed Nov 2, 2017 14:24 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 942 | $7.17 | $6,754.14 |
DisclosureSEC source: 0001214659-17-006343 · marketforms-40046.xml · nonDerivative · entry 1 Johnson Steven Ernest · CIK 0001685633 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2017 Filed May 2, 2017 18:52 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 747 | $9.03 | $6,745.41 |
DisclosureSEC source: 0001214659-17-002939 · marketforms-38716.xml · nonDerivative · entry 1 Johnson Steven Ernest · CIK 0001685633 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 17:40 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-16-149814 · doc4.xml · derivative · entry 1 Johnson Steven Ernest · CIK 0001685633 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2026-11-09 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, commencing on December 9, 2016, with 100% of the total shares vested on November 9, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.